Year: 2024
Type: editorial
Abstract: In this issue of Blood, Hassan et al 1 have identified GADD45A as a pivotal tumor suppressor that acts as a key downstream target of leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4), which governs the self-renewal capacity and therapy resistance of LGR4/HOXA9-dependent acute myeloid leukemia (AML) stem cells (LSCs).This finding suggests a potential novel therapeutic avenue for targeting LSCs in LGR4/HOXA9dependent AML by restoring GADD45A expression. AML is a clonal malignancy originating from LSCs and characterized by
Source: Blood
Authors: Zhijian Qian, Fang Yu
Institution: University of Florida
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4400317271